Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity

Obesity Research

Volumn 8, Issue 1, 2000, Pages 49-61

  Rössner, Stephan ^a   Sjöström, Lars ^b   Noack, Rudolf ^c   Meinders, A Edo ^d   Noseda, Giorgio ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Ospedale Beata Vergine   (Switzerland)

Author keywords

Cardiovascular risk factors; Lipase inhibition; Orlistat; Quality of life; Weight loss

Indexed keywords

ANTIOBESITY AGENT; LACTONE; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LOW CALORY DIET; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; CARDIOVASCULAR SYSTEM; DIET, REDUCING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; PLACEBOS; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0033629936     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2000.8     Document Type: Article

References (30)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the Unites States: prevalence and trends, 1960-1994. Int J Obes. 1998;22:39-47.
2. Björntorp P. Obesity. Lancet. 1997;350:423-6.
3. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677-85.
4. McGinnis JM, Toege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-12.
5. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes. 1997;21(Suppl. 1):S5-9.
6. Goldstein DI. Beneficial health effects of modest weight loss. Int J Obes. 1992;16:397-415.
7. Hyman FN, Sempos E, Saltsman J, Glinsmann WH. Evidence for success of caloric restriction in weight loss and control: summary of data from industry. Ann Intern Med. 1993;119:681-7.
8. Guerciolini R. Mode of action of orlistat. Int J Obes. 1997; 21(Suppl. 3):S12-23.
9. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? BMJ. 1995;311:437-9.
10. Rolls B, Shide DJ. The influence of dietary fat on food intake and body weight. Nutr Rev. 1992;50:283-90.
11. Blundell JE, Lawton CL, Hill AJ. Mechanisms of appetite control and their abnormalities in obese patients. Horm Res. 1993;39(Suppl. 3):72-6.
12. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992;5: 309S-13S.
13. Zhi J, Melia AT, Guerciolini R, Chung J, Kingberg J, Hauptman JR. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56:82-5.
14. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes. 1993;17: 241-4.
15. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes. 1995;19:221-6.
16. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-72.
17. Van Gaal LF, Broom JI, Enzi G, Toplak H, and the Orlistat Dose Ranging Study Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6 month dose ranging study. Eur J Clin Pharmacol. 1998;54:125-32.
18. Mathias SD, Williamson CL, Colwell HH, et al. Assessing health-related quality of life and health state preference in persons with obesity: a validation study. Qual Life Res. 1997; 6:311-22.
19. Pfohl M, Luft D, Blomberg I, Schmulling R-M. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes. 1994;18:391-5.
20. Thomas PR. Weighing the options. Criteria for evaluating weight management programs. Institute of Medicine, Washington (DC): National Academy Press; 1995.
21. Skender ML, Goodrick GK, Del Junco DJ, et al. Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions. J Am Diet Assoc. 1996;96:342-6.
22. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13: 123-36.
23. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;ii:1142-5.
24. Ryan DH, Bray GA, Williamson DA, Champagne CM. Treatment for 2 1/2 years with sibutramine. Obes Res. 1996; 4(Suppl. 1):AO73.
25. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol. 1994;46:405-10.
26. Larsson B. Obesity and body fat distribution as predictors of coronary heart disease. In: Marmot M, Elliott P, eds. Coronary Heart Disease Epidemiology. From Aetiology to Public Health. Oxford: Oxford University Press; 1992. p. 233-41.
27. Lean ME, Han TS, Morrison CE. Waist circumference as a measure indicating need for weight management. BMJ. 1995; 311:1150-62.
28. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ. 1995;311:1401-5.
29. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996; 36:647-53.
30. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol. 1996;36:152-9.